Teva Pharmaceutical Industries Ltd (TEVJF) EBT Margin (2009 - 2026)
Teva Pharmaceutical Industries' (TEVJF) quarterly EBT Margin came in at 10.99% in Q2 2026, down 1585.0% YoY from 0.74% in Q2 2025, and down 200.1% on a QoQ basis from 10.97% in Q1 2026.
Teva Pharmaceutical Industries Ltd (TEVJF) EBT Margin (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVJF) has 18 years of EBT Margin data on file, last reported at 10.99% in Q2 2026.
- Quarterly EBT Margin fell 1585.0% year-over-year to 10.99% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 4.09% (up 457.0% YoY) and the FY2025 annual result came in at 7.09%, up 1485.0% from the prior year.
- EBT Margin fell to 10.99% in Q2 2026, from 10.97% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 14.42% in Q3 2025 to a low of 39.38% in Q4 2023.
- A 5-year average of 7.42% and a median of 6.67% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin tumbled 3899 bps — and 2024, when it jumped 3086 bps.
- Tracing TEVJF's EBT Margin over 5 years: stood at 30.51% in 2022, then declined by 29 bps to 39.38% in 2023, then jumped by 78 bps to 8.52% in 2024, then surged by 120 bps to 1.7% in 2025, then slumped by 747 bps to 10.99% in 2026.
- The last three EBT Margin figures came in at 10.99% (Q2 2026), 10.97% (Q1 2026), and 1.7% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.99% |
| Mar 31, 2026 | 10.97% |
| Dec 31, 2025 | 1.70% |
| Sep 30, 2025 | 14.42% |
| Jun 30, 2025 | 4.86% |
| Mar 31, 2025 | 7.56% |
| Dec 31, 2024 | -8.52% |
| Sep 30, 2024 | -7.48% |
| Jun 30, 2024 | -5.91% |
| Mar 31, 2024 | 12.23% |
| Dec 31, 2023 | -39.38% |
| Sep 30, 2023 | 1.66% |
| Jun 30, 2023 | -23.80% |
| Mar 31, 2023 | -7.43% |
| Dec 31, 2022 | -30.51% |
| Sep 30, 2022 | 4.76% |
| Jun 30, 2022 | -31.11% |
| Mar 31, 2022 | -26.52% |
| Dec 31, 2021 | -4.27% |
| Sep 30, 2021 | 9.83% |